Related Experiment Video

Updated: Jun 8, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Consequences of targeted treatments for second-line therapy

E De Maio1, C Tibaldi, A D'Incecco

  • 1Ospedale Civile, Medical Oncology, Livorno, Italy.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|October 15, 2010
PubMed

Insights

The first-line treatment for metastatic non-small cell lung cancer (NSCLC) now requires precise tumor histology and EGFR status. This impacts second-line therapy choices due to early use of agents.

Area of Science:

  • Medical Oncology
  • Thoracic Oncology
  • Clinical Trials

Background:

  • First-line treatment for relapsed or metastatic non-small cell lung cancer (NSCLC) is evolving.
  • Accurate tumor histology and epidermal growth factor receptor (EGFR) status are critical for selecting initial therapies.

Purpose of the Study:

  • To discuss the implications of targeted first-line treatments on subsequent second-line therapy options in metastatic NSCLC.
  • To analyze how the evolving treatment landscape affects available choices at disease progression.

Main Methods:

  • Review of large phase III clinical trials.
  • Analysis of treatment strategies based on tumor characteristics (histology, EGFR status).
  • Evaluation of maintenance therapy's impact on subsequent treatment lines.

Main Results:

  • EGFR-activating mutations predict sensitivity to EGFR-tyrosine kinase inhibitors.
  • Non-squamous histology benefits from agents like bevacizumab or pemetrexed.
  • Maintenance therapy (pemetrexed, docetaxel, erlotinib) is effective in metastatic NSCLC.

Conclusions:

  • The shift towards targeted first-line therapies and early maintenance strategies significantly impacts second-line treatment options for metastatic NSCLC.
  • Limited therapeutic choices may arise at disease progression due to early agent utilization.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...